Intermediate HCC – The evolving role of IO In this final episode of the four-part series on hepatocellular carcinoma (HCC), hosted by the Oncology Brothers Drs Rohit and Rahul Gosain, the discussion focuses on the evolving role of immunotherapy (IO) in intermediate HCC. The episode explores multimodal approaches that combine IO and IO-based therapies with loco-regional treatments and highlights the essential role of a multidisciplinary care team. Joined by Drs Nina Sanford (radiation oncologist), Mark Yarchoan (medical oncologist) and Ed Kim (interventional radiologist), the experts provide a brief overview of current treatment options for intermediate HCC, addressing its heterogeneity and standard treatment pathways. They delve into the latest clinical trial data (EMERALD-1, LEAP-012) on combining IO with loco-regional therapies, discussing clinical implications. The conversation also underscores the importance of effective collaboration within the multidisciplinary team for delivering optimal patient care. The episode concludes with future perspectives in the field and key clinical takeaways on integrating IO with loco-regional therapy and the significance of multidisciplinary care in managing HCC. Key clinical takeaways: IO and IO-based treatments are moving earlier in the treatment paradigm for patients with intermediate HCC. Earlier integration of these therapies aims to achieve improved systemic control, allowing loco-regional therapy to target oligoprogression, residual lesions or reduce tumour burden Emerging data supports combining systemic and loco-regional therapies for patients with intermediate HCC. EMERALD-1 and LEAP-012 show promising PFS data using IO-based combination regimens like durvalumab + bevacizumab or pembrolizumab + lenvatinib alongside TACE. Long-term OS data are awaited Effective communication and coordinated care among specialists, such as medical oncologists, radiation oncologists, hepatologists, and interventional radiologists, are essential to developing optimal treatment strategies for patients with intermediate HCC You can also watch a video of the experts in conversation and download the accompanying slides and transcript on our website: https://cor2ed.com/hcc-connect/programmes/intermediate-hcc-the-evolving-role-of-io/ Or watch on YouTube: https://www.youtube.com/watch?v=3voWa0U96lE Follow us on social media: LinkedIn: https://www.linkedin.com/company/hcc-connect/ X https://x.com/hccconnectinfo This content is intended for healthcare professionals only. The medical experts in this podcast are expressing their own views and not those of COR2ED, Supporters or their institution. AstraZeneca has provided a sponsorship grant towards this independent programme. This podcast is developed by cor2ed.com Published on January 2025 Subscribe to this channel to stay up to date with new Independent Education programmes as they’re released. <...

Ask this episode

“What did the council decide on item 42?” — answered with the speaker and the moment.

Transcript

Related